on 13 Jun 2023
Last Applicant/ Owned by
21 JJ Thomson Ave
Cambridge
GB
CB30FA
Serial Number
90461564 filed on 12th Jan 2021
Registration Number
7081259 registered on 13th Jun 2023
Correspondent Address
Mary Frances Love
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
The wording SAJAZIR has no meaning in a foreign language. Pharmaceutical agents for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; pharmaceutical preparations forRead More
Pharmaceutical agents for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; pharmaceutical preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; pharmaceuticals for the treatment of hereditary angioedema all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; Veterinary preparations for treatment of intestinal bacteria; veterinary preparations, namely, antioxidants; veterinary preparations, namely, pain relief medications; veterinary preparations for medical treatment of chronic illnesses; veterinary preparations for treatment of viral diseases; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; dietary supplements for humans and animals; supplements for the treatment of hereditary angioedema; supplements for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; food for babies; medical dressings; plasters for medical purposes; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; biological preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels and transdermal patches; chemical preparations for the medical treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels and transdermal patches; Drug delivery agents consisting of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents for use in pharmaceutical preparations, drugs and medicines for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; medical drugs for the treatment of rare diseases, in particular for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; enzyme preparations for medical purposes, enzyme preparations for the treatment of hereditary angioedema, medical enzyme preparations in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; enzyme preparations for veterinary purposes; medicinal preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; medicines for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; Medical and veterinary preparations and articles, namely, pre-filled syringes containing a bradykinin B2 receptor antagonist for medical purposes; Pharmaceuticals and natural remedy preparations, for use in the treatment and management of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist; syringes sold filled with a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema
23rd Sep 2022
23rd Sep 2022
No 90461564
No Service/Collective Mark
No 14218-102
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
13th Jun 2023 | REGISTERED-PRINCIPAL REGISTER |
13th Jun 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
09th May 2023 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
08th May 2023 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
04th May 2023 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
04th May 2023 | STATEMENT OF USE PROCESSING COMPLETE |
18th Apr 2023 | TEAS STATEMENT OF USE RECEIVED |
18th Apr 2023 | USE AMENDMENT FILED |
18th Oct 2022 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
23rd Aug 2022 | PUBLISHED FOR OPPOSITION |